Bionyra Pharma’s pipeline consists of two medication that focus on the signaling protein TL1A, alone and as a part of a mix method to deal with inflammatory problems. The startup’s launch makes it a contender in an rising drug class that features late-clinical property from Merck, Roche, and companions Sanofi and Teva Prescribed drugs.
The publish Irritation Startup Bionyra Launches With $165M and Ex-Sanofi Exec on the Helm appeared first on MedCity Information.
